Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Medical management of lower urinary tract symptoms in men: current treatment and future approaches

Nature Clinical Practice Urology volume 5, pages 211–219 (2008)Cite this article

Abstract

Lower urinary tract symptoms (LUTS) are extremely common in men and, in addition to causing considerable bother, can lead to the development of complications, such as acute urinary retention. Over the past couple of decades, developments in the medical management of LUTS in men have led to a substantial decline in the number of surgical procedures being performed to treat associated disorders, such as prostatectomy for benign prostatic enlargement. In this Review we summarize the available treatments and discuss the latest data on the use of anticholinergics and phosphodiesterase type-5 inhibitors for this indication. We also review the various combinations of medical therapies that have been reported in the literature to optimize the management of LUTS in men. In addition, there is a growing realization that LUTS in men are not synonymous with prostatic disease, and in many patients overactive bladder syndrome is the cause or a component of the LUTS experienced; we have, therefore, taken the opportunity to try to clarify the terminology used in LUTS in men, since there is the potential for considerable confusion with the terms that are currently in common usage in any discussion of this disorder.

Key Points

  • Although terminology regarding lower urinary tract symptoms (LUTS) in men and their underlying disorders has evolved, it remains confusing, and terms describing the nature of the LUTS (voiding or storage) might be more appropriate, particularly when the underlying diagnosis is unknown

  • Improved understanding of the role of overactive bladder syndrome and storage symptoms in the etiology of LUTS in men has led to a paradigm shift away from the disorder being equated with prostatic disease or bladder outlet obstruction

  • The aims of medical therapy for LUTS in men should be to improve the bothersome symptoms and/or reduce progression of the disease

  • The availability of effective medical treatments for LUTS has led to a dramatic decline in the number of prostatectomies that are performed

  • Enhanced understanding of the underlying causes of male LUTS has led to an interest in the role of anticholinergics and phosphodiesterase type-5 inhibitors in the management of LUTS

  • Combination therapy might optimize medical management but much further research is needed to develop appropriate regimens, and cost-effectiveness and the cumulative adverse affects must also be borne in mind

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Wei JT et al. (2005) Urologic diseases in America project: benign prostatic hyperplasia. J Urol 173: 1256–1261

    Article  Google Scholar 

  2. Chute CG et al. (1993) The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 150: 85–89

    Article  CAS  Google Scholar 

  3. Roehrborn CG et al. (2006) Enlarged prostate: a landmark national survey of its prevalence and impact on US men and their partners. Prostate Cancer Prostatic Dis 9: 30–34

    Article  CAS  Google Scholar 

  4. Issa MM and Regan TS (2007) Medical therapy for benign prostatic hyperplasia—present and future impact. Am J Manag Care 13 (Suppl 1): S4–S9

    PubMed  Google Scholar 

  5. Irwin DE et al. (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50: 1314–1315

    Article  Google Scholar 

  6. Hashim H and Abrams P (2006) Is the bladder a reliable witness for predicting detrusor overactivity? J Urol 175: 191–194

    Article  CAS  Google Scholar 

  7. Abrams P et al. (2002) The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21: 167–178

    Article  Google Scholar 

  8. Berry SJ et al. (1984) The development of human benign prostatic hyperplasia with age. J Urol 132: 474–479

    Article  CAS  Google Scholar 

  9. Lytton B et al. (1968) The incidence of benign prostatic obstruction. J Urol 99: 639–645

    Article  CAS  Google Scholar 

  10. Jacobsen SJ et al. (1997) Natural history of prostatism: risk factors for acute urinary retention. J Urol 158: 481–487

    Article  CAS  Google Scholar 

  11. McConnell J et al. (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 338: 557–563

    Article  CAS  Google Scholar 

  12. Ball AJ et al. (1981) The natural history of untreated “prostatism”. Br J Urol 53: 613–616

    Article  CAS  Google Scholar 

  13. European Association of Urology Guidelines (2007). Guidelines on benign prostatic hyperplasia [http://www.uroweb.org/fileadmin/user_upload/Guidelines/11%20BPH.pdf] (accessed 4 February 2008)

  14. Crawford ED et al. (2006) Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 175: 1422–1426

    Article  CAS  Google Scholar 

  15. Madersbacher S et al. (2004) EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 46: 547–554

    Article  Google Scholar 

  16. Chapple CR (2004) Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician. BJU Int 94: 738–744

    Article  Google Scholar 

  17. Chapple C et al. (2006) New medical developments in the management of LUTS in adult men (World Health Organisation Report—Committee 6). In Male Lower Urinary Tract Dysfunction, 143–194 (Eds McConnel J et al.) Jersey: Health Publications Ltd

    Google Scholar 

  18. Nordling J (2005) Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int 95: 1006–1012

    Article  CAS  Google Scholar 

  19. Roehrborn CG (2001) Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Urology 58: 953–959

    Article  CAS  Google Scholar 

  20. Mobley DF et al. (1997) Effect of doxazosin on the symptoms of benign prostatic hyperplasia: results from three double-blind placebo-controlled studies. Int J Clin Pract 51: 282–288

    CAS  PubMed  Google Scholar 

  21. Chapple CR et al. (1996) Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol 29: 155–167

    CAS  PubMed  Google Scholar 

  22. MacDonald R and Wilt TJ (2005) Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects. Urology 66: 780–788

    Article  Google Scholar 

  23. Wilt TJ et al. (2002) Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. J Urol 167: 177–183

    Article  CAS  Google Scholar 

  24. Barendrecht MM et al. (2005) Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system. BJU Int 95 (Suppl 4): 19–28

    Article  CAS  Google Scholar 

  25. van Kerrebroeck P et al. (2002) Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study. Eur Urol 41: 54–60

    Article  CAS  Google Scholar 

  26. Chapple CR et al. (1997) Tamsulosin 0.4 mg once daily: tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH). The European Tamsulosin Study Group. Eur Urol 32: 462–470

    CAS  PubMed  Google Scholar 

  27. Lowe FC (1997) Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect. Clin Ther 19: 730–742

    Article  CAS  Google Scholar 

  28. Lowe FC (2005) Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function. BJU Int 95 (Suppl 4): 12–18

    Article  CAS  Google Scholar 

  29. Kloner RA et al. (2004) Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 172: 1935–1940

    Article  Google Scholar 

  30. Chang DF and Campbell JR (2005) Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg 31: 664–673

    Article  Google Scholar 

  31. Chapple CR (2005) The Oral Controlled Absorption System (OCAS®): the evolution of tamsulosin for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH). Eur Urol Suppl 4: 20–22

    Article  CAS  Google Scholar 

  32. Speakman MJ et al. (2004) Guideline for the primary care management of male lower urinary tract symptoms. BJU Int 93: 985–990

    Article  CAS  Google Scholar 

  33. Bruskewitz R et al. (1999) Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology 54: 670–678

    Article  CAS  Google Scholar 

  34. Andriole GL and Kirby R (2003) Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 44: 82–88

    Article  CAS  Google Scholar 

  35. Edwards JE and Moore RA (2002) Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials. BMC Urol 2: 14

    Article  Google Scholar 

  36. Roehrborn CG et al. (2004) Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 63: 709–715

    Article  Google Scholar 

  37. McConnell JD et al. (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349: 2387–2398

    Article  CAS  Google Scholar 

  38. Barkin J et al. (2003) Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol 44: 461–466

    Article  CAS  Google Scholar 

  39. Baldwin KC et al. (2001) Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology 58: 203–209

    Article  CAS  Google Scholar 

  40. Kaplan SA and Gonzalez RR (2007) Phosphodiesterase type 5 inhibitors for the treatment of male lower urinary tract symptoms. Rev Urol 9: 73–77

    PubMed  PubMed Central  Google Scholar 

  41. Uckert S et al. (2001) Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 166: 2484–2490

    Article  CAS  Google Scholar 

  42. Adolfsson PI et al. (2002) Lysophosphatidic acid stimulates proliferation of cultured smooth muscle cells from human BPH tissue: sildenafil and papaverin generate inhibition. Prostate 51: 50–58

    Article  CAS  Google Scholar 

  43. Mulhall JP et al. (2006) Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 3: 662–667

    Article  CAS  Google Scholar 

  44. McVary KT et al. (2007) Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 177: 1401–1407

    Article  CAS  Google Scholar 

  45. McVary KT et al. (2007) Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 177: 1071–1077

    Article  CAS  Google Scholar 

  46. Kaplan SA et al. (2007) Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 51: 1717–1723

    Article  CAS  Google Scholar 

  47. Crawford ED (2005) Management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the central role of the patient risk profile. BJU Int 95 (Suppl 4): 1–5

    Article  Google Scholar 

  48. GlaxoSmithKline (online 22 December 2004) Study Number: ARI40001 – Year 1. [http://ctr.gsk.co.uk/Summary/dutasteride/studylist.asp] (Accessed 13 January 2008)

  49. Kaplan S et al. (2000) Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. The Pless Study Group. Urology 56: 610–616

    Article  CAS  Google Scholar 

  50. de Nunzio C et al. (2003) The evolution of detrusor overactivity after watchful waiting, medical therapy and surgery in patients with bladder outlet obstruction. J Urol 169: 535–539

    Article  Google Scholar 

  51. Abrams P et al. (2006) Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 175: 999–1004

    Article  CAS  Google Scholar 

  52. Blake-James BT et al. (2007) The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. BJU Int 99: 85–96

    Article  CAS  Google Scholar 

  53. Kaplan SA et al. (2005) Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 174: 2273–2275

    Article  Google Scholar 

  54. Lee KS et al. (2005) Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol 174: 1334–1338

    Article  CAS  Google Scholar 

  55. Kaplan SA et al. (2006) Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 296: 2319–2328

    Article  CAS  Google Scholar 

  56. Yang Y et al. (2007) Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. Chin Med J (Engl) 120: 370–374

    Article  CAS  Google Scholar 

  57. Novara G et al. (2006) Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: a systematic review. Eur Urol 50: 675–683

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. AK Patel is a Urology Research Fellow and CR Chapple is Professor of Urology and a Consultant Urological Surgeon, Royal Hallamshire Hospital, Sheffield, UK.,

    Anand K Patel & Christopher R Chapple

Authors
  1. Anand K Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher R Chapple
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher R Chapple.

Ethics declarations

Competing interests

AK Patel declared no competing interests.

CR Chapple serves as a consultant and has received grants and/or research support from Allergan, Astellas, Novartis and Pfizer. He is also a member of the speakers bureau and receives honoraria from Astellas and Pfizer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Patel, A., Chapple, C. Medical management of lower urinary tract symptoms in men: current treatment and future approaches. Nat Rev Urol 5, 211–219 (2008). https://doi.org/10.1038/ncpuro1060

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpuro1060

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing